Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Genesis Revenues Up 65% At Half Year

Auckland, New Zealand, 7 August 2001 – Biotechnology company Genesis Research [NZSE & ASX: GEN] today announced revenues for the six months to 30 June 2001 of $12.6 million (2000: $7.6 million), up 65% and a net deficit for the period of $1.7 million (2000 deficit: $4.0 million). At period end Genesis held cash reserves of $51.6 million (2000: $13.1 million).

Expenditure on research and development during the period rose to $ 11.3 million (2000: $8.7 million), up 30%.

“Genesis’ cash reserves are sufficient to fund current and planned research and development activities for several years,” said Chairman David Irving. “In addition, unlike many biotechnology companies, which depend on capital injections until products are commercialised, Genesis is substantially self-funding as the revenue growth shows. Genesis continues to build long term value by developing its patents and databases, gene sequencing expertise, numerous therapeutics and discovery programmes and joint venture partnerships.”

“The period has seen significant advancements in our ability to commercialise biotechnology intellectual property for both the international pharmaceutical industry and plant-based industries,” said Chief Executive, Dr Jim Watson. “Continuing that advancement, we plan to increase expenditure in the second half of 2001 as we expand our clinical trial programmes. We also plan to commit further research funds to new science programmes that apply our genomics capability to targets in therapeutics and plant science.”

Genesis’ Therapeutics Division now has three drug candidates in clinical trial programmes for psoriasis, atopic dermatitis and asthma. In conjunction with our partner Corixa Corporation, the next PVAC™ psoriasis trial to be conducted in the USA is being designed. This will focus on patients whose immune systems have not been compromised by severe immuno-suppressive treatments. The Phase I trial of AVAC™ for the treatment of asthma is nearing completion in Wellington, and a Phase I trial of AVAC™ for the treatment of atopic dermatitis has commenced, also in Wellington. It will run for most of 2001.

The Discovery Division has achieved significant milestones in a number of partner programmes. The forestry team continues to provide substantial research effort for ArborGen LLC, the joint venture between Genesis, Rubicon, Westvaco Corporation and International Paper, developing specific traits for forestry trees. The first phase of the Wrightson EST sequencing project has been completed, yielding what is believed to be the world’s largest forage grass EST database and mirroring the approach Genesis previously used successfully in the forestry industry. The bovine collaboration with AgResearch has also completed its database construction phase and Genesis is now independently mining this wealth of gene information for product development opportunities in human health. Genesis is also pursuing the early commercial targets in joint ventures for the use of BioStore including storage of blood platelets and red cells.

The Genomics Division has invested in new technologies and is now equipped to undertake larger scale automated sequencing projects and provide enhanced bioinformatics capabilities. This has improved Genesis’ ability to build and mine EST databases to find novel genes that have potential commercial value.

Staff numbers have increased from 128 at 31 December 2000 to 143 at 30 June 2001 to meet business plan objectives.

ENDS

About Genesis
Genesis is a New Zealand based biotechnology company committed to the building of a strong genomic platform for the development of innovative products in human health and agriculture. Genesis partners with industry leaders to target products that have global market potential through the mining of its extensive microbe, plant and mammalian EST databases. Genesis has three programs in human clinical development, with additional programs in pre-clinical development and in plant biotechnology. Genesis was founded in 1994 in Auckland, New Zealand. For more information, please visit www.genesis.co.nz.


© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Hospitality NZ: Hospitality Wages Jump 9% To Pass Living Wage
Wages and salaries across the hospitality sector continue to increase despite businesses having to battle through some of the toughest trading periods in living memory... More>>



Climate Leaders Coalition: Launches New Statement Of Ambition, Appoints New CEO Convenor

The Climate Leaders Coalition is tonight officially launching a new Statement of Ambition to accelerate business action on climate change... More>>


Retail: New Law Paves Way For Greater Supermarket Competition

Legislation that bans major supermarkets from blocking their competitors’ access to land to set up new stores paves the way for greater competition in the sector, Minister of Commerce and Consumer Affairs Dr David Clark said... More>>



MYOB: New Data Shows Increase In SMEs Experiencing Stress And Anxiety

The lingering impacts of the COVID-19 pandemic have led to a surge in the number of local SME owners and operators experiencing stress and anxiety, according to new research from business management platform, MYOB... More>>



Carbonz: Cashing In On Carbon: The New Marketplace Helping Native Forest To Thrive

The country’s first voluntary carbon credit marketplace, Carbonz, is here to restore native biodiversity and help Aotearoa reach its carbon zero goals by selling the first carbon credits exclusively from native forest... More>>
Entrust District: Dividend Will Be Welcomed After Another Tough Year
We’ve all heard of the saying; “if it sounds too good to be true, it probably is” but for Aucklanders within the Entrust District, getting their share of Entrust’s 2022 annual dividend payment really is as good as it sounds... More>>